CervoMed Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
28.3%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$2.15next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly12.9MTarget: Sufficient capital to fund operations into Q2 2027 following the June 2026 private placement and registered direct offerings
Neflamapimod Phase 2a nfvPPA Trial Enrollment and Biomarker Data AnnuallyTarget: Complete enrollment and report initial 24-week biomarker and clinical data in the second half of 2026
EXPERTS-ALS Phase 2a Trial Dosing AnnuallyTarget: Dose the first ALS patient with neflamapimod in the fourth quarter of 2026
Watch Items
- Strategic Partnership for Phase 3 DLB TrialTrigger: Execution of a definitive global co-development or licensing agreementAction: Initiate the global, pivotal Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB)
- Cash Runway and Going Concern StatusTrigger: Cash reserves falling below 6 months of operating expenses without a strategic partner or additional financingAction: Implement further cost-containment measures or execute additional dilutive equity/debt financing
Research as of 19 Jun 2026